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Ras-related TC21 is activated by mutation in a breast
cancer cell line, but infrequently in breast carcinomas
in vivo
KT Barker and MR Crompton
Institute of Cancer Research. Haddow Laboratones. 15 Cotswold Road. Sutton SM2 5NG Surrey. UK
Summary Activating ras mutations are found in many types of human tumour. Mutations in Harvey (H-). Kirsten (K-) and neuronal (N-) ras
are, however, rarely found in breast carcinomas. TC21 is a rasfamily member that shares close homology to H-. K- and N-ras. and activating
mutations have been found in ovarian carcinoma and leiomyosarcoma cell lines. We have examined panels of cDNAs from breast. ovarian
and cervical cell lines, and primary and metastatic breast tumours for mutations in TC21 using a single-strand conformational polymorphism
(SSCP)-based assay. One breast cancer cell line. CAL51 exhibited an altered SSCP pattem, compared with normal tissue, which was due to
an A-T base change in codon 72, causing a predicted Gln-Leu activating mutation. Of nine primary and 15 metastatic breast tumour cDNAs
analysed, none exhibited an altered pattem by SSCP. The apparently wild-type pattem by SSCP analysis was confirmed by sequence
analysis of some of the cDNAs assayed. Thus. we conclude that mutations in TC21 are uncommon in breast carcinomas.
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Mammalian ras genes encode a familv of small GTPases involved
in signal transduction pathx -ax-s leading to cell growth and differ-
entiation. RAS proteins are inactive in the GDP-bound state and
are actixated in response to receptor protein txrosine kinases or
other stimuli to become GTP bound (Barbacid. 1987). Guanine
nucleotide exchange factors (GEFs) positixelv reaulate RAS b-
promoting the active GTP-bound form: and GTPase-actixvatina
proteins (GAPs) negatixelv regulate RAS by accelerating the
GTPase actix-itx of RAS (review-ed in Bo2uski and McCormick.
1993). Actixe RAS interacts Awith effectors to transduce its sianals.
the most well-characterized interaction being, that w-ith RAF-1.
Actix-e RAS binds to REF-1 and recruits it to the plasma
membrane. where it actixvates the MAP kinase pathway. This leads
to several 'do%vnstream exvents'. including control of rene tran-
scription (reviewed by- Marais and Marshall. 1996).
Mutated ras genes wvere first discovered because of their abilitv
to transform NIH/3T3 cells after DNA transfection. Subsequently.
many human tumours were show-n to harbour ras point mutations.
most commonly in codons 12. 13 and 61 (Bos. 1989). Alterations in
these amino acids lead to a decreased rate of GTP hN-drolsis or a
failure to respond to GAP. thus resulting in an accumulation of
active GTP-bound RAS. Harxev (H)-. Kirsten (K)- and neuronal
(N)-ras w-ere the first to be identified. and are the most w-ell-charac-
terized w-ith respect to mutational status in tumours. There is a large
Xariation in the frequency of mutations between tumour txpes. The
hinhest incidence thus found is in pancreatic tumours. where over
80% hax-e mutated K-ras genes. w%-hereas mutations are rarely seen
in either H-. K- or N-ras in breast tumours (Bos. 1989: Clark- and
Der. 1995). Ras mutations hax-e been described in some mucinous
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oxarian cancers (Ichikaxxa et al. 1994: Cuatrecasas et al. 1997). but
generally appear to be a rare ex-ent in ox-arian carcinomas xvan t
Veer et al. 1988: Berchuck and Carnev. 1997). The incidence in
cervical cancer is not as clear. some reports describe a high
frequency of ras mutations (Riou et al. 1988: Wong et al. 1995).
others haxe found a verx lowx frequencv (Bos. 1988: Willis. 1993).
One possible explanation for the absence of ras mutations in
breast cancer could be that deregulation of RAS function does not
lead to uncontrolled growth of breast epithelial cells. Human
phaeochromocytomas do not haxe mutations in ras. and the
introduction of oncogenic RAS into PC12 cells. w-hich are rat
phaeochromocytoma cells. leads to differentiation and groxxth
arrest (Bar-Sagi and Feramisco. 1985: Noda et al. 1985). This does
not appear to be the case for breast epithelial cells. For example.
expression of oncogenic H-ras leads to the transformation of the
breast epithelial cell line MCF 1OA (Basolo et al. 1991). Elex ated
lexvels of H-ras product have been detected in human breast
tumours (Watson et al. 1990). Another possibility is that deregula-
tion of RAS pathways xia other mechanisms not inxolxing muta-
tions in ras genes may be important. Alternatixely. other members
of the ras family may play more major roles in growth control in
breast cancer. and mutations may be found in these genes.
TC2 1 is a ras family member cloned from a human teratocarci-
noma cell line. It shoxws overall 60%' nucleotide and 55%1c amino
acid identity w-ith H-. K- and N-ras. xith a strictly conserxed
effector domain (Dri-as et al. 19%). This is the closest homoloax
to H-. K- and N-ras genes ofany of the ras superfamilx cloned to
date. There are sexeral pieces ofexidence to suggest that TC21 may
play a role in human cancer. Codons 22. 23 and 72 in TC21 are
analogous to those A-hose in xvixo mutation leads to oncogenic acti-
xation in H-. K- and N-ras (Graham et al. 1994). Ahen codons 22
and 72 wxere experimentally mutated in TC2 1. 22 Glu to Val. and 72
Gln to Leu. the result was a transforming actixvitx equivalent to that
ofoncogen c ras (Graham et al. 1994. A form ofthe 72 Gln to Leu
mutation in TC2 1 has been cloned from an ox arian carcinoma cell
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line (Chan et al. 1994). and the transforming capacity and tumon-
genicity of this mutation in NIH/3T3 cells was confirmed. An
insertional mutation of 9 bp at codon 24 in TC21 has been identi-
fied in a human leiomyosarcoma cell line. and this displays high
transforming activity in NlH/3T3 cells (Huang et al, 1995).
Whereas most experiments on transformation by mutant TC21
have been performed in murine fibroblast cells, mutants 22 Glu to
Val and 72 Gln to Leu have been shown to transform MCF lOA.
spontaneously immortalized human mammary epithelial cells
(Soule et al. 1990). causing altered cell morphology and allowing
colony formation in soft agar (Clark et al, 1996). It is therefore
possible that aberrant TC21 signalling may be involved in breast
tumour progression. To examine the possibility that TC21 may be
mutated in breast cancer, we have developed a single-strand
conformational polymorphism (SSCP)-based assay to look for
equivalent mutations in breast cancer cell lines and primary and
metastatic breast carcinomas. In view of the low incidence of K-
and H-ras mutations reported in ovarian tumours, and the identifi-
cation ofaTC21-activating mutation in an ovarian cancercell line.
A2780. we surveyed a panel ofovarian cancercell lines. ras muta-
tions may play an important role in the progression of cervical
cancer. but the reported frequency of mutation varies between
studies. As altemative ras gene family members may be mutated
in those not harbouring K- or H-ras mutations. we examined a
panel of cervical carcinomas and cell lines for activating TC21
mutations.
MATERIALS AND METHODS
SSCP
RNA was isolated using the RNAgents® Total RNA Isolation
System (Promega). by a modification ofthe method ofWilkinson
(1988) or using guanidinium isothiocyanate (Chirgwin et al. 1979).
cDNA was prepared as described previously (Barker et al. 1995).
Oligonucleotides primers 5'TACCGGCTCGTGGTGGTCGG3'
(sense) and 5'TATCTGTGACTGAAAAGACC3' (antisense) were
designed to amplify a 249-bp region ofTC21 from nucleotides 40
to 289, spanning all three potential activating mutation sites
Amplifications were carried out using cDNA derived from 0.2 jg
of orginal RNA in 60 mM KCI 15 mm Tris-HCI pH 8.8. 1.75 mM
MgCl,. 200 of each dNTlP 3 jCi [a-'2PJdCIT. 20pmol ofeach
pnmer and 1 unit of Taq polymerase in 25 j. Each reaction was
cycled 30 times at 94°C for 1 min, 550C for 2 min and 720C for
1 min. An aliquot of 4 of each reaction was mixed with 4 of
SSCP gel loading buffer (95% deionized fonnamide, 0.025 M EDTA
pH 8.0.0.005% bromophenol blue, 0.005% xylene cyanol). heated at
95°C for 5 min. and chilled on ice for 1 min. Undenatuned samples
were kept on ice. An aliquot of4 ofeidter denatured or undena-
tured samples was loaded onto 6% acrylamnide, x TBE, 10%
glycerol gels. Fragments were resolved by electophoresis at 5 W for
15 h; gels were dried and exposed to X-ray film at-70°C ovemnight
Subcloning and sequencing
PCR reactions were carried out as for SSCP but without [3n-P]
dCTP. Amplified products were resolved on 1.5% agarose TAE
gels, excised and purified using a QLAEX H Gel Extraction Kit
(Qiagen). Purified products were subcloned into the pGEMI-T
Easy vector (Promega) according to the manufacturer's instruc-
tions. Sequences were determined by the dideoxy method of
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Fxgure 1 SSCP analysis ofTC21 mRNA. SSCP analysis was performed on
cDNAs from norMal tissue and te ovaran carcinoma cell line A2780 (A),
and from breast cancer cell fines (B). Altered mobdity bands are indicated by
arrows, asterisks mark bands of unknown oin
Sanger et al (1977) using a Sequenase Version 2.0 kit (United
States Biochemicals. USB).
Direct PCR sequencing
PCR amplifications were carried out either as above for
subcloning. or with cloned Pfu DNA polymerase (Stratagene).
using the manufacturer's buffer and 200gM of each dNTP.
Amplified products were purified using a QIAEX II Gel
Extraction Kit. Sequence reactions using a Sequenase Version 2.0
Kit (USB) were performed on approximately 30 ng of purified
product and an excess ofprimer (1 ig 10 jl ').
RESULTS
SSCP analysis of breast cancer cell lines
The genomic structure of TC21 has not yet been reported. there-
fore mutation analysis was performed on cDNA. Primers that
bracket the region containing all three potential activating muta-
tion sites were used to amplify a single band of the predicted size
by PCR. SSCP gel running conditions that detect an altered
mobility caused by a single base pair change were assessed using
cDNA from normal mammary tissue. and from the ovarian cell
line A2780. which has an A-T transversion in codon 72 leading to
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Figure 2 Nucleotide sequence of TC21 mRNA at codon 72. Normal cDNA
shows wild-type sequence, CAA (gin), CAL51 reveals a mutabon CTA (leu)
a Gin to Leu mutation (Chan et al. 1994) (Figure IA). Two bands
representing two complementary strands were observed, and there
was a shift in mobility of the higher band in the A2780-derived
PCR product compared with the normal tissue as expected (Huang
et al. 1995). Ten breast carcinoma cell lines were examined
(Figure lB). The cell line MDA MB 415 failed to amplify a
product on two independent determinations. MDA MB 157. -231.
-468 (not shown), SKBr3. BT474, MCF 7. ZR75.1 and T-47D all
exhibited a wild-type pattern on SSCP analysis. SSCP analysis of
cDNA from MCF 1OA cells revealed a wild-type pattern ofbands.
consistent with the observations that these cells when transfected
with mutant TC21 exhibit altered morphology and enhanced
growth in soft agar. One cell line. CAL51 (Gioanni et al. 1990).
revealed a shift in mobility of the upper band characteristic of the
pattern seen with A2780 cells. The bands marked with arrows in
Figure lB represent the two complementary strands. Extra bands
are sometimes seen (marked with an asterisk): these are irrepro-
ducible and are not indicative of sequence changes.
TC21 is mutated in CAL51 cells
To investigate the cause of the shift in mobility seen in the SSCP
analysis of CAL51 cell line cDNA. the sequence of the derived
PCR product was determined. An A to T base change in codon 72.
causing a predicted Gln-Leu mutation identical to that seen in the
cell line A2780. was seen. Figure 2 shows the sequence ofCAL51
in this region compared with the wild-type TC21 sequence from
normal tissue. SSCP analysis ofA2780 failed to detect a wild-type
allele; this is consistent with the observations of Huang et al
(1995). A wild-type allele was not observed in the SSCP analysis
of CAL51 cells also. and sequencing revealed only the mutant
sequence at this codon. Sequencing of the PCR products of other
breast cancer cell lines confirmed the SSCP results. in that only
wild-type sequences were present (data not shown).
SSCP fails to detect TC21 mutations in ovarian or
cervical cancer cell lines
Twelve ovarian and eight cervical cancer cell lines were examined
for TC21 mutation by SSCP. Amplified products were detected
using cDNA from eight of the ovarian and seven of the cervical
cell lines. and in all cases the SSCP analysis gave a wild-type
pattern. When two of the cell line PCR products were sequenced.
only wild-type sequences were observed.
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FKgure 3 SSCP analyss of a panel of primary and metastatc breast
tumour cDNAs. Mutant pattems are exhibited by A2780 and CAL51 cDNAs.
The tumour cDNAs all show te same pattem as the normal tissue
Lack of TC21 mutation in a panel of primary and
metastatic breast tumours
Five normal mammary tissue-derived cDNAs were subjected to
SSCP analysis and all gave wild-type TC21 pattems. Each of nine
primary breast cancers that gave an amplified TC21 product gave a
wild-type pattem. Of 15 metastatic breast tunmour firom lymph
nodes. 13 produced a wild-type TC21 pattem. Figure 3 shows a
representative sample. whereas one product produced an apparently
altered pattern. This cDNA and one obviously normal cDNA were
amplified by PCR and sequenced. Sequencing of the product from
one node revealed some silent changes with respect to the published
cDNA sequence. but none resulting in amino acid changes.
DISCUSSION
The low frequency of H-. K- and N-ras mutations in breast
tumours has led us to undertake this study to examine the possi-
bility that the ras superfamily member TC21 is mutated in breast
cancers. None of the nine primary or 15 metastatic breast
carcinoma samples that we analysed were mutant for TC21. We
conclude that TC21 mutations are an infrequent event in the devel-
opment of breast tumours. Of the panel of breast. ovarian and
cervical cancer cell lines analysed, only one. the breast carcinoma
cell line CAL51, had a mutation in TC21.
CALS1 cells were isolated from amalignant pleural effusion of a
woman with a metastatic breast adenocarcinoma. The cells exhibit
morphological. structural and immunohistochemical characteristics
of mammary epithelial cells. They will form colonies in soft agar
and are tumorigenic in nude mice (Gioanni et al. 1990). Unlike the
majority of established breast carcinoma cell lines they have an
apparently normal karyotype (Gioanni et al. 1990; S Birdsall.
personal communication). The genetic alterations responsible for
the neoplastic phenotype ofCAL51 are not known (they lack muta-
tions in the p53 gene. Theile et al. 1994). To our knowledge. this
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mutation in TC21 is the onl- genetic aberration reported forCAL51
cells. Ahen this mutant form (72. Gln-Leu) was transfected into
MICF1OA cells. it conferred the abilitv to form colonies in soft a2ar.
but not tumorigenicitv in nude mice (Clar-k et al. 1996). It is
possible that the ability ofCAL51 cells to form colonies in soft agar
is at least partially due to this mutation in TC21.
Mutations in ras genes do not appear to be a common event in
breast. cervical or ovarian tumours (with the possible exception of
mucinous ovarian tumours. see Introduction). Although it could be
hypothesized that cell type-specific differences in the likelihood of
acquiring co-operating mutations account for the apparent tumour
type bias of ras mutations. the deregulation of RAS pathways in
the development of tumours such as those of the breast should not
be discounted. Activated RAS is able to transform breast epithelial
cells (Basolo et al. 1991). and chemicallv induced rat mammary
tumours harbour ras mutations (Sukumar. 1990). Human breast
epithelial cells transformed by carcinogens acquire activatingy
ras mutations (Zhang et al. 1994). In addition. several studies in
transgenic mice have found that activated and/or overexpressed
ras alleles can predispose to the development of mammary
tumours (Andres et al. 1987: Sinn et al. 1987: Mangyues et al.
1992). In view of the above findingys. there is a possibility that
other components of RAS signalling pathways are altered in
breast. cervical and ovarian tumours. thus having the equi-alent
effect without an activating ras mutation. Oncogyenic RAS is less
sensitive to GAPs leading to an accumulation of active GTP-
bound RAS: a reduction in GAP activity could have the same
effect as mutated RAS. The two best characterized mammalian
RAS GAPs are p'2O GAP and NFl GAP. Neurofibromatosis type
I (NF ) is an autosomal dominant condition that predisposes to
certain types of carcinoma. There is evidence to suggest that NFl
may function as a tumour suppressor (Legius et al. 1993): this may
be due to decreased RAS-GAP activitv. Tumours and cell lines
derived from tumours from NFl patients have decreased NE1
GAP activitv and increased levels of RAS-GTP (Basu et al. 1992:
DeClue et al. 1992: Bollag et al. 1996: Guha et al. 1996). NFl
mutations have also been found to occur in spontaneously arising
tumours (Li et al. 1992: Andersen et al. 1993). However. some cell
lines established from tumours occumn2 in non-NFl patients have
reduced levels ofNFl but not elevated RAS-GTP levels (Johnson
et al. 1993). It may be that loss of NT1 function(s) independent
from GAP activitv play a role in the phenotype of these cells. It is
hypothesized that GAPs may function as downstream effectors of
RAS in addition to theirregulatory activity (Clark and Der. 1995).
There have been cases of breast cancers of an aggressive nature
reported in NFl patients (Teh et al. 1997). It may therefore prove
informative to make a more detailed analyNsis of NFl or p12O GAP
expression and sequence in breast and other tumours.
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